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Transcriptional Regulation of the Murine
39 IgH Enhancer by OCT-2
element itself can render B cell specificity to an unre-
lated core promoter in transcription assays both in vivo
and in vitro (Dreyfus et al., 1987; Wirth et al., 1987;
Hong Tang and Phillip A. Sharp*
Center for Cancer Research
and Department of Biology
Massachusetts Institute of Technology Annweiler et al., 1994). Indeed, transgenic experiments
Cambridge, Massachusetts 02139 indicate that the octamer motif is the most critical regu-
latory element for B cell±specific activity of the 59 VH
promoter (Jenuwein and Grosschedl, 1991). In B cells,
the octamer element is recognized by the Oct-1 andSummary
Oct-2 proteins, which share a highly conserved bipartite
Targeted disruption of either of the B cell±specific POU domain, consisting of a homeodomain (POUH) and
transcription factors Oct-2 or OCA-B/BOB-1/OBF-1 a POU-specific domain (POUS; Herr et al., 1988). As
dramatically affects B cell terminal differentiation. The contrasted to the POU domain, the N and C termini of
39 enhancer of immunoglobulin heavy chain (IgH) locus Oct-1 and Oct-2 are very divergent. These two proteins
is important for transcription of the locus in terminal are thought to have distinct roles in the regulation of
plasma cells. Allele-specific suppression of mutant immunoglobulin gene expression. Oct-1 is a ubiquitous
Oct-2 binding sites in this enhancer by a variant Oct-2 factor expressed in most cell types, while Oct-2 is pre-
protein revealed that in a mature B cell line this en- dominantly B cell±specific and essential for terminal dif-
hancer was specifically dependent upon Oct-2, as ferentiation of B cells (Matthias, 1998). Reconstitution
contrasted to the closely related Oct-1 transcription of SCID or RAG2/2 mice with Oct-22/2 fetal liver cells
factor. Phosphorylation of the Oct-2 protein was im- reveals that the development of B cells in the bone
portant for this activation and was synergistic for co- marrow is normal, yet the number of mature B cells is
activation by the OCA-B factor. These results indicate dramatically reduced in blood and lymphoid organs.
that Oct-2 and OCA-B interact with the 39 enhancer in These chimeras have reduced serum levels of IgM, IgG1,
regulation of the IgH locus during B cell activation. IgG3, and IgG2b (Corcoran and Karvelas, 1994; Humbert
and Corcoran, 1997). The possibility that Oct-2 might
be important for secretion of these Ig isotypes is sup-
Introduction
ported by the concordant expression patterns of Oct-2
and Ig secretion in response to IL-6 during B cell terminal
Key regulatory elements for transcriptional control of
differentiation (Natkunam et al., 1994).the IgH locus include the 59 proximal promoter (59 VH), OCA-B (OBF-1, Bob-1) is a B cell±specific cofactor ofthe intronic enhancer (Em), and the 39 IgH enhancer.
Oct-1 or Oct-2 that directly interacts with these proteins.The murine 39 IgH enhancer spans z30 kb and is located
It also makes specific protein-base contacts in the majorz4 kb downstream of the constant gene Ca. It consists
groove of the conserved octamer element (Cepek etof four DNase I hypersensitive segments, designated
al., 1996). Like Oct-22/2 mice, early stages of B cellCa39E (Matthias and Baltimore, 1993), HS1/2 (Petters-
development in the bone marrow are not affected inson et al., 1990; Dariavach et al., 1991; Lieberson et al.,
OCA-B2/2 mice. Germinal center formation is completely1991), HS3, and HS4 (Madisen and Groudine, 1994). The
abolished in OCA-B2/2 mice, with decreased serum ti-importance of individual enhancer elements may vary
ters of IgA, IgG1, IgG2a, IgG2b, IgG3, and IgE but notduring B cell differentiation, but they concert, together
IgM (Kim et al., 1996; Nielsen et al., 1996; Schubart etwith Em, to exert their effects (Madisen and Groudine,
al., 1996), although the development of plasma cells is1994; Chauveau et al., 1998; Ong et al., 1998). Transfec-
intact (Qin et al., 1998).tion experiments also indicate that HS1/2-HS3-HS4
The molecular mechanisms by which Oct-2 exerts itsfunctions as a locus control region (LCR) active during
transactivation are still vague, although its activationlate stages of B cell development (Madisen and Grou-
and repression domains have been mapped by usingdine, 1994; Madisen et al., 1998). These elements may
artificial promoters or enhancers (Tanaka and Herr,be redundant, as gene targeting of Ca39E or HS1/2
1990; Tanaka et al., 1994; Friedl and Matthias, 1995).(Manis et al., 1998) or a naturally occurring deletion of
An increasing body of evidence indicates that Oct-2 isCa39E and HS1/2 (Saleque et al., 1999) does not affect
probably important for the 39 IgH enhancer activity. First,IgH gene expression or class switching recombination
transfection into a WEHI 231 cell line deficient in Oct-2(CSR), but a spontaneous deletion of the entire 39 en-
indicates that this factor is not required for octamer-hancer region causes a severe reduction in IgH expres-
specific promoter function but is essential for activitysion in a plasmacytoma cell line (Gregor and Morrison,
from an artificial octamer-containing enhancer (Feldhaus1986; Michaelson et al., 1995).
A highly conserved octamer binding site, 59-ATGC et al., 1993). Second, DNase I footprinting experiments
AAAT-39 (octWT), is present in all promoters and en- showed in vivo that the octamer motif within HS1/2 be-
hancers of the IgH gene (Matthias, 1998). The octamer comes protected in response to activation of B cells by
either lipopolysaccharide (LPS) treatment, IgM cross-
linking, or CD40 ligation (Arulampalam et al., 1994; Grant* To whom correspondence should be addressed (e-mail: sharppa@
mit.edu). et al., 1995, 1996). Third, as mentioned above, Oct-22/2
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mice strains are defective in B cell terminal differentia-
tion and in secretion of certain Ig isotypes, the cellular
functions regulated by the 39 IgH enhancer.
Cell culture experiments indicate that Oct-2 is also
required for normal humoral responses to both T cell±
dependent (TD) and T cell±independent (TI) antigens
(Humbert and Corcoran, 1997). Therefore, Oct-2 may
serve as a target for LPS and cytokine-driven signal
transduction involved in B cell terminal differentiation
(Coffman et al., 1993). During this transition, LPS induces
both B cell differentiation and proliferation (Kearney and
Lawton, 1975; Kearney et al., 1976). The protein kinase
C (PKC) signaling pathway is activated by LPS (Rush
and Waechter, 1987; Gupta et al., 1988; Li et al., 1992;
Yuan et al., 1992) and may regulate Ig synthesis and
secretion (Li et al., 1992; Yuan et al., 1992; Arulampalam
et al., 1994).
We have investigated the functional importance of the
interactions of Oct-2 with the 39 IgH enhancer during
B cell terminal differentiation. We establish that Oct-2
directly regulates 39 IgH enhancer activity and that phos-
phorylation of Oct-2 is an important aspect of this regu-
lation. We also demonstrate a synergistic activation of
Oct-2 by OCA-B when B cells are activated by LPS.
Results
Requirement of the Octamer Motif for the 39 IgH
Enhancer Function
The 39 IgH enhancer contains four highly conserved oc-
Figure 1. Construction of 39 IgH Enhancer Reporter Vectors andtamer sites, suggesting that a unique role of Oct-2 in B Transient Transfection Analyses
cell development might depend on its binding to these
(A) The wild-type enhancer reporter (pGL3-VE) contains luciferase
sites. To test the dependence on octamer sites in the gene (gray oval), whose expression is driven by the 59 VH (hatched
39 IgH enhancer, each of the four conserved octamer oval), and a combination of HS1/2 (dotted box), HS3 (gray box), and
sites in the construct pGL3-VE was substituted with HS4 (open box). The conserved octamer motif within each enhancer
segments (open circle) was mutagenized to octGG (cross) to yieldoctGG (ATGCAAGG; Pomerantz and Sharp, 1994) to cre-
mutant reporter pGL3-VE/1±4GG (see Experimental Procedures).ate pGL3-VE/1-4GG (Figure 1A). When these two con-
The conserved octamer motif within 59 VH was kept intact in orderstructs were transfected into a series of different B cell
to facilitate analysis of ªcross-talkº between the promoter and thelines corresponding to different developmental stages
enhancer. The reference octamer-dependent promoter reporter
of B cells, only the M12 line, a nonsecreting mature B pGL3-VH contains the 59 VH (hatched oval), and the octamer site
cell line (Laskov et al., 1981), exhibited a clear depen- was mutated to octGG (cross) analogously to yield pGL3-VH-GG.
dence on the presence of the octamer sequences (Fig- (B) Octamer dependence. pGL3-VE (3 mg; black bar) or pGL3-VE/
1±4GG (3 mg; open bar) were transiently transfected into different cellure 1B). The construct containing the wild-type en-
lines representing developmental stages at the pre-B (HAFTL), Bhancer was consistently 2- to 3-fold more active than
(WEHI 231), or mature B cell (M12, MOPC 31, MPC 11, and S194).that containing the mutant octamer sites. This octamer
Luciferase activities were measured 43 hr postelectroporation. Repre-dependence of the 39 IgH enhancer was neither ob-
sentative results were shown as the relative luciferase activity of mu-
served in other mature, Ig-secreting plasmacytoma tant/wild-type reporter averaged from two independent transfections.
lines, for example, MPC 11, MOPC 31, or S194, nor in (C) Comparison of the enhancer versus enhancerless reporter activ-
the pre-B cell line HAFTL or the B cell line WEHI 231 ity. M12 cells were transfected with 3 mg pGL3-Basic, pGL3-VH,
pGL3-VE, and pGL3-VE/1±4GG, and luciferase activities were aver-(Figure 1B). Moreover, the dependence of the enhancer
aged from three independent assays with SD presented as erroron the octamer elements was partial because the mutant
bars.enhancer construct had 4-fold higher activity than en-
hancerless 59 VH construct (Figure 1C). This is not sur-
prising, as the enhancer is known to bind other transacti-
POU), specifically recognizes octGG with high affinity andvating factors (Grant et al., 1995; Michaelson et al., 1996;
specificity (Pomerantz and Sharp, 1994). In order to setLinderson et al., 1997). This suggests that the octamer
up an enhancer reporter system that is responsive tosites within the enhancer might have a more critical and
exogenous Oct-2 protein, an altered DNA-binding speci-physiological role in transcription activity in the M12 cell
ficity mutant of Oct-2 was constructed. Since the POUline than many other B cell lines.
domain is highly conserved between Oct-1 and Oct-2,
the corresponding mutations V343R/N347R of Oct-2Establishment of an Altered DNA-Binding
(Oct-2RR) should also bind with affinity and specificity toSpecificity System
the same variant octamer sequence. To confirm this,We have previously found that a double mutation of
the homeodomain of Oct-1, V425R and N429R (Oct-1RR both full-length octamer binding factors and arginine
Oct-2 and the 39 IgH enhancer
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Figure 2. Gel Shift Analysis of Altered DNA-Binding Specificity Mu-
tants of Oct-1RR and Oct-2RR
Wild-type and RR mutant derivatives of Oct-1 and Oct-2 were pro-
duced as described (see Experimental Procedures). Lysates (4 ml)
containing Oct-1 (lane 2) and Oct-1RR (lane 3) or Oct-2 (lane 4) and
Oct-2RR (lane 5) were used in EMSA. The amount of Oct-1 or Oct-1RR
was about two times less than Oct-2 or Oct-2RR as quantified by the
incorporation efficiency of 35S-methionine in a separated in vitro
translation reaction (data not shown). (A) 0.5±1 nM of octWT or (B)
octGG DNA probe was used. Lane 1 was mock reactions with 4 ml
reticulocyte lysates. The apparent Kd was measured in a separate
experiment not shown here, and the midpoint of binding was shown.
mutant proteins were generated by translation in vitro
and their DNA-binding activities at octWT or octGG site
were assessed by electrophoretic mobility shift assays
(EMSA; Figure 2). As expected, wild-type Oct-1 and
Oct-2 proteins selectively bound to wild-type octamer
probe with .25-fold higher affinity than the Oct-1RR and
Oct-2RR proteins (Figure 2A, compare lanes 2 and 3 and Figure 3. Differential Transcription Activity of Oct-1 and Oct-2 at
the 39 IgH Enhancerlanes 4 and 5). Also as expected, Oct-1RR or Oct-2RR
(A) pGL3-VE/1±4GG (black bar) was transient transfected into M12protein bound the variant octamer site octGG site with
with pCG-FLAG-Oct-1 or pCG-FLAG-Oct-2 or with their suppressor.15-fold or .20-fold higher affinity than wild-type Oct-1
mutants, pCG-FLAG-Oct-1RR or pCG-FLAG-Oct-2RR (hatched bars).or Oct-2 protein, respectively (Figure 2B, compare lanes
Cells were treated with 50 mg/ml LPS overnight before being ana-
2 and 3 and lanes 4 and 5). Previous results have shown lyzed. Specific activity was derived by comparison of reporter activ-
that Oct-1RR POU domain protein binds to the octGG site ity of the alanine mutant proteins versus wild-type octamer binding
with 150-fold lower affinity than that of the Oct-1 POU proteins. The bottom panel represents the immunoblotting of each
FLAG-tagged Oct proteins expressed under assay conditions nor-domain protein for the octWT site (Pomerantz and Sharp,
malized against b-galactosidase activities.1994). This difference is not apparent from the experi-
(B) pGL3-VH (black bar) and pGL3-VH-GG (gray bar) were transientment shown in Figure 2B, where higher Oct-related pro-
transfected analogously into M12, together with pCG-FLAG-Oct-1
tein concentrations were assayed in the presence of or pCG-FLAG-Oct-2 or with their suppressor mutants, pCG-FLAG-
added nonspecific DNA. The important observation is Oct-1RR or pCG-FLAG-Oct-2RR (hatched bars). Data are presented
that Oct-2RR exhibits allele-specific binding, which is as the relative luciferase activity of that with overexpressed Oct
proteins versus with reporter vector alone.consistent with our previous studies on DNA-binding
activity of the Oct-1RR POU domain at the octGG site
(Pomerantz and Sharp, 1994) and reminiscent of recent
genetic screening results (Shah et al., 1997). compared with FLAG-Oct-1 (Figure 3A, compare lanes
4 and 5 and lanes 2 and 3). This stimulation was allele
specific, as the enhancer reporter was not significantlyOct-2 but Not Oct-1 Is Active at the 39 IgH Enhancer
DNA sequences encoding the FLAG epitope were in- stimulated by overexpression of either the wild-type
Oct-1 or Oct-2 proteins (Figure 3A, lanes 2 and 4). Theserted at the N terminus of the wild-type or arginine
mutant Oct-2 proteins and the plasmids were transiently slight increase in the enhancer reporter activity may
be due to increased 59 VH promoter activity caused bycotransfected into the M12 cell line with the reporter
pGL3-VE/1-4GG. In this assay, cells were treated with overexpressed wild-type Oct-1 or Oct-2 (Figure 3B). The
protein expression levels were verified by Western blot-LPS to increase the total stimulation of expression (see
below). Overexpression of FLAG-Oct-2RR increased re- ting using the M5 anti-FLAG mAb (Figure 3A, bottom
panel). Moreover, both the wild-type and arginine mu-porter activity by z4-fold compared to that with FLAG-
Oct-2. However, overexpression of Oct-1RR did not dra- tant variant Oct-1 or Oct-2 proteins were active when
overexpressed in M12 cells. This was indicated by theirmatically increase expression of the reporter gene as
Immunity
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not treated with LPS. LPS dramatically increased Oct-
2RR-dependent enhancer activity as contrasted to the
much more modest stimulation when the mutant re-
porter was transfected alone (Figure 4B). The LPS en-
hancement was dose dependent (data not shown) and
did not reach a plateau even after 24 hr.
The most likely mechanism for LPS stimulation of B
cell differentiation is through the PKC signaling pathway,
which is independent of Ca21 mobilization and phos-
phoinositol turnover (Dearden-Badet and Revillard, 1993;
Mey and Revillard, 1998). To test if this is the case,
the levels of Oct-2RR-dependent enhancer activity were
assayed when LPS treatment was performed in the
presence of different kinase inhibitors: staurosporine
(80 nM) for PKC, HA1004 (20 mg/ml) for protein kinase
A (PKA), genestein (30 mM) for PTK, PB95058 (4 mM) for
MAPKp42, and SB203580 (2 mM) for MAPKp38. Stauro-
sporine inhibited the reporter activity by 6-fold, while
the other inhibitors had marginal effects, indicating that
LPS activation of Oct-2-dependent transcription might
act through the PKC pathway. At this concentration,
staurosporine was previously shown to specifically in-
hibit LPS stimulation of IgM production in B cells (Yuan
et al., 1992).
The LPS signaling pathway involves phosphorylation
Figure 4. Mitogenic Effects of LPS on M12 Cells of target proteins by PKC. Optimal substrate sites for
(A) Induction of Blimp-1 expression verified by RT±PCR. M12 (lanes phosphorylation by PKC have been determined (Nishi-
1 and 2), MPC 11 (lanes 3 and 4), and S194 (lanes 5 and 6) cells kawa et al., 1997) and were used to predict potential
were treated with 50 mg/ml LPS overnight. Blimp-1-specific cDNA
PKC phosphorylation targets within the Oct-2 protein.(upper panel) was amplified by RT±PCR (primers: GGACTGGGTGGA
Thr-302 and Ser-303 of the Oct-2 POUH domain scoredCATGAGAGAG/GAAGTACCCCCGTCAGCGCCG). The gel loading
strongly as putative phosphorylation targets for PKCswas normalized by the control amplification of b-actin (lower panel).
(B) Time course of Oct-2RR-dependent enhancer activity in response (SP $ 3 and probability $ 75%; data not shown). The
to LPS. M12 cells were transiently transfected with pGL3-VE/1±4GG same sites are good substrates for protein kinase A
alone (triangle) or cotransfected with pGL3-VE/1±4GG and pCG- (PKA), and the identical conserved serine residue of the
Oct-2RR (circle). Luciferase activities with LPS (filled) or without LPS Oct-1 POUH domain has been shown to be phosphory-(open) were measured at different time points as indicated.
lated by PKA (Segil et al., 1991).
To evaluate the contribution of T302 and S303 to
phosphorylation of Oct-2, each or both of these sites
ability to transactivate an octamer-dependent reporter,
were mutated to alanine in FLAG-Oct-2-T302A, FLAG-
pGL3-VH, or its octGG variant, pGL3-VH-GG (Figure 3B; Oct-2-S303A, or FLAG-Oct-2-T302A/S303A. These con-
for plasmid construction, see Figure 1). These results structs were transfected into M12 cells, which were
strongly indicate that Oct-2 has a unique function when then treated with LPS, and metabolically labeled with
interacting with the 39 IgH enhancer in the M12 cells. 32P-orthorphosphate. Extracts prepared from these cells
were immunoprecipitated with FLAG antibodies. The au-
Oct-2 May be Modified by Protein Kinase C toradiographs of the immunoprecipitates revealed that
The activation of B cells by the T cell±independent stim- the T302A and S303A mutations diminished significantly
ulus LPS is defective in Oct-22/2 B cells in culture (Cor- the level of phosphorylation of Oct-2, suggesting that
coran et al., 1994; Humbert and Corcoran, 1997). To these two sites probably serve as the major phosphory-
first test whether M12 cells respond to LPS treatment lation targets for PKC in vivo (Figure 5A, upper panel).
for limited differentiation, RT±PCR was performed to In parallel, the total amount of FLAG-Oct-2 proteins im-
verify the upregulation of B lymphocyte±induced matura- munoprecipitated was determined by Western blotting
tion protein (Blimp-1) expression, a specific molecular with antisera specific to Oct-2 (Figure 5A, lower panel).
marker of early plasma cells (Turner et al., 1994). As All four transfections yielded similar levels of Oct-2 re-
shown in Figure 4A, LPS treatment of M12 cells en- lated polypeptides.
hanced Blimp-1 expression by more than 5-fold, while The phosphorylation of Oct-2 by PKC in vitro was
the same stimulus failed to change the levels of the analyzed by two-dimensional phosphopeptide mapping
Blimp-1 transcript in MPC11 or S194 cells (upper panel). using either recombinant Oct-2 POU domain protein or
This result indicates that LPS can drive M12 cells to T302A, S303A mutant variants (see Experimental Proce-
further differentiate into plasma cells, the transition dures). The wild-type Oct-2 POU domain showed a dis-
phase essentially dependent upon Oct-2 protein ac- tinct pattern of tryptic fragments (Figure 5B, solid arrows
tivity. in panel I) of which two disappeared in T302A mutant
To determine whether LPS can potentiate Oct-2-depen- derivative (Figure 5B, panel II) and one disappeared in
dent 39 IgH enhancer activity, M12 cells cotransfected S303A variant (Figure 5B, panel III). Because the phos-
phorylation was done with purified conventional PKCwith pGL3-VE/1±4GG and Oct-2RR were either treated or
Oct-2 and the 39 IgH enhancer
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the potential tryptic fragment (amino acids 299±310)
containing T302 and S303 was synthesized and subject
to the analogous phosphorylation and two-dimensional
mapping (see Experimental Procedures). Trypsin diges-
tion of the phosphopeptide generated two fragments
(Figure 5B, panel V) that comigrated with those from the
trypsin digestion of the full-length Oct-2 POU domain
when the two samples were mixed and run together
(Figure 5B, panel IV). Thus, alanine mutation at T302 and
S303 inactivates phosphorylation at these sites by PKC,
consistent with a reduction in the level of phosphoryla-
tion in vivo with mutant analogs.
Oct-2 May Contain a Novel Transactivation Domain
Functioning at the 39 IgH Enhancer
The roles of the two potential PKC target residues in
regulation of the 39 IgH enhancer by Oct-2 were exam-
ined by cotransfecting M12 cells with the Oct-2RR-
dependent reporter and plasmids encoding FLAG-Oct-2RR
containing the T302A, S303A, or T302A/S303A muta-
tions. If reporter basal activity was subtracted, the re-
porter activity was reduced slightly with Oct-2RR-T302A
compared to that of Oct-2RR, by 3-fold with Oct-2RR-
S303A, and almost vanished with double mutant Oct-
2RR-T302A/S303A (Figure 5C, upper panel). The muta-
tions did not effect the stability of the Oct-2 proteins as
Western blotting of extracts from the transfected M12
cells revealed comparable levels of Oct-2 proteins (Fig-
ure 5C, lower panel). These results suggest that phos-
phorylation of T302 and S303 of Oct-2 is critical for
Figure 5. Characterization of Alanine Mutants at Potential PKC Sites transactivation by Oct-2 at the 39 IgH enhancer.
on Oct-2RR-Dependent Enhancer Activities The reduction in reporter enhancer activity caused by
(A) In vivo 32P labeling to assess phosphorylation states of wild-type the T302A and S303A mutations in Oct-2 could be due
and alanine mutants of Oct-2. FLAG-tagged Oct-2 (20 mg; lane 2), to defects in DNA binding. In the Oct-1 POU domain/
Oct-2-T302A (lane 3), Oct-2-S303A (lane 4), and Oct-2-T302A/S303A
DNA complex, the equivalent threonine residue of Oct-1(lane 5) were transfected into M12 (two of 100 mm dishes) with 50
makes a side-chain contact with the phosphosugarmg/ml LPS for 23 hr before immunoprecipitation. Protein loading
backbone (Klemm et al., 1994). To show whether thewas normalized using rabbit anti-Oct-2 serum by a separate immu-
noblotting (lower panel), so that equal amounts of wild-type and alanine mutation affects the DNA binding activity of
mutant Oct-2 proteins were used to measure the intensity of 32P Oct-2, EMSA was performed using nuclear extracts pre-
incorporation (upper panel). pared from LPS-treated M12 transfectants containing
(B) Top panel: two-dimensional phosphopeptide mapping of Oct-2
overexpressed Oct-2RR or its alanine mutants. The probePOU domains phosphorylated by PKC. His-Oct-2 POU (I), His-Oct-2
containing octGG was used to detect DNA binding byPOU/302A (II), and His-Oct-2 POU/303A (III) (z2000 cpm of each)
the transfected Oct-2RR variants but not endogenouswere loaded for TLC (see Experimental Procedures). Solid arrows
indicate tryptic peptides specific for T302 and/or S303; open arrows factors. Oct-2RR and the alanine mutant derivatives were
indicate those without T302 and/or S303 residues. Inserts indicate able to bind to DNA with similar affinity (Figure 6A, lanes
total phosphorylated proteins before TPCK-trypsin digestion and 5, 7, 9, and 11). The low level of complex formation by
ovals indicate the loading origins. Bottom panel: 1000 cpm (IV) or
Oct-2RR-T302A (lane 7) and Oct-2RR-T302A/S303A (lane4000 cpm (V) of POU2 WT phosphopeptide was either mixed with
11) were due to their relatively lower protein expressiontrypsin-digested His-Oct-2 POU or loaded alone, respectively.
levels (data not shown). Moreover, the differences in(C) Analysis of transactivation by potential PKC target mutants of
Oct-2 (top panel). Six micrograms of either pCG-FLAG-Oct-2RR, transcriptional activation by Oct-2RR and its alanine mu-
pCG-FLAG-Oct-2RR-T302A, pCG-FLAG-Oct-2RR-S303A, or pCG- tant derivatives were not due to differences in their sub-
FLAG-Oct-2RR-T302A/S303A was transiently cotransfected with 3 cellular localization, as each protein had an identical
mg of pGL3-VE/1±4GG into M12 cells in the presence of 50 mg/ml
nuclear localization when examined by fluorescenceLPS for 23 hr before luciferase assays. The amount of FLAG-tagged
immunostaining against the FLAG epitope (data notOct-2 proteins expressed was verified by immunoblotting with M5
shown).anti-FLAG antibodies (bottom panel).
As mentioned above, previous studies have shown
that PKA phosphorylation of Oct-1 at the site equivalent
to S303 inactivated DNA binding. This apparent contra-preparations (containing a, b, g, d, and other isozymes),
the POU domain was significantly phosphorylated at diction with the binding of phosphorylated Oct-2 was
investigated using EMSA to assess DNA binding as asites other than those altered in the T302A or S303A
variants (Figure 5B, open arrows). Phosphorylation at function of phosphorylation of Oct proteins. PKA specifi-
cally phosphorylated Oct-2 POU at T302 and S303 (Fig-these sites did not vary among the three proteins and
is considered nonspecific. A peptide corresponding to ure 6B, bottom panel; data not shown), which mimicked
Immunity
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Figure 7. Effects of OCA-B at the 39 IgH Enhancer
M12 was transiently cotransfected with pGL3-VE/1±4GG alone
(black bar), 2 mg pCATCH-Bob-1/OCA-B (dotted bar), or pCG-Oct-
2RR alone (gray bar), or in combination with either 6 mg of pCG-Oct-
2RR or various alanine mutants of Oct-2RR (hatched bars). Enhancer
reporter activities were measured 23 hr after electroporation in the
presence of 10 mg/ml LPS.
of the 39 IgH enhancer, a plasmid expressing OCA-B
was transiently cotransfected with the plasmid express-
Figure 6. Protein±Protein Interaction between Oct-2 and OCA-B
ing Oct-2RR into M12 cells. The M12 cells were treated
(A) EMSA analysis of potential alanine mutants. Nuclear extracts
for 24 hr with LPS. Coexpression of Oct-2RR with OCA-Bwere prepared from transfectants used in previous transfection ex-
stimulated the reporter activity by more than 25-foldperiments, and EMSA was performed using octGG as the probe (see
as compared to that with OCA-B alone, or z6 fold ifExperimental Procedures). Equal amounts of total nuclear proteins,
as judged by the Bradford assay, containing Oct-1RR (lanes 3 and compared to that with Oct-2RR alone (Figure 7), indicating
4), Oct-2RR (lanes 5 and 6), Oct-2RR-T302A (lanes 7 and 8), Oct-2RR- that OCA-B coactivates with Oct-2. This activation could
S303A (lanes 9 and 10), or Oct-2RR-T302A/S303A (lanes 11 and 12) reflect a synergism between Oct-2RR and OCA-B at the
were used. Lanes 1 and 2 showed nuclear extracts from a mock
enhancer or interaction of overexpressed OCA-B withtransfection. GST-OCA-B (150 ng) was used in the supershift reac-
an octamer protein bound to the intact 59 VH.tions (lanes 2, 4, 6, 8, 10, and 12).
The OCA-B protein possesses activation domains(B) Differential DNA binding by phosphorylated Oct protein. EMSA
analysis of DNA binding by Oct-2 POU domains in the function of (Babb et al., 1997) and its overexpression and recruit-
phosphorylation by PKA. Sixty nanograms of Oct-1 POU (lanes 3±5), ment to the 39 IgH enhancer by Oct-2 could potentially
Oct-2 POU (lanes 6±8), Oct-2 POU/302A (lanes 9±11), and Oct-2 bypass the need for phosphorylation of Oct-2 in activa-
POU/303A (lanes 12±14) from PKA kinase reaction were used (see
tion of the 39 IgH enhancer. To test this possibility, tran-Experimental Procedures). Reaction with the free probe (lane 1) and
sient cotransfection analyses were performed withPKA alone (lane 2) was also shown.
OCA-B and the alanine mutants of Oct-2RR. Overexpres-
sion of OCA-B failed to alleviate the defect resulting
from alanine substitution of T302 or S303 of Oct-2RR, withclosely the specific phosphorylation patterns of Oct-2
S303 being more critical for such synergistic activationPOU domain by PKC in vivo (Figure 5A). With increasing
(Figure 7). It is unlikely that mutation of either these twoconcentrations of PKA, the Oct-2 POU domain main-
residues would have direct effects on the binding oftained its binding activity regardless of the level of pro-
OCA-B to the Oct-2/octamer complex. This notion istein phosphorylation (Figure 6B, top panel, lanes 6±8).
supported by EMSA, in which addition of purified fusionA similar DNA-binding behavior was also observed with
protein GST-OCA-B generated a supershift of DNA com-less-phosphorylated T302A and S303A Oct-2 POU do-
plexes containing either Oct-2 or its alanine mutantsmains (lanes 9±11 and 12±14). Strikingly, also in agree-
(Figure 6A, lanes 6, 8, 10, and 12). Therefore, we con-ment with previous observations (Segil et al., 1991), in-
clude that phosphorylation of Oct-2 is required for acti-creasing phosphorylation of the Oct-1 POU domain
vation of the 39 IgH enhancer by the coactivator OCA-B.strongly inhibited its DNA binding (lanes 5).
Synergy between Oct-2 and OCA-B Discussion
at 39 IgH Enhancer
The phenotypes of OCA-B2/2 mice partially overlap Allele-specific interactions between a variant sequence
of the octamer site, octGG, and a mutant Oct-2 proteinthose of an Oct-2 null mutant, indicating that these two
factors may interact for normal B cell development. To with two arginine substitutions, Oct-2RR, has shown that
the 39 IgH enhancer is dependent upon the Oct-2 proteindetermine whether OCA-B is involved in the regulation
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in the plasmacytoma cell line M12. This dependence is and abrogates LPS stimulation of Oct-2-dependent en-
hancer activity. These observations would be antici-specific for Oct-2 as contrasted to Oct-1, which has the
pated by the involvement of a PKC signaling pathway.same DNA-binding specificity. Activation of the 39 IgH
Alanine mutation of the predicted PKC targets T302 andenhancer by Oct-2 is stimulated by LPS treatment, prob-
S303 both reduced the level of phosphorylation of theably due to phosphorylation of threonine and serine
mutant Oct-2 proteins during B cell activation and re-residues located in the linker segment between the two
duced the potential of these proteins to activate the 39subdomains of the POU domain. Mutations of these
IgH enhancer.sites to alanine inactivate Oct-2 in this transcriptional
The dependence of Oct-2 activity upon phosphoryla-context. Furthermore, overexpression of the cofactor
tion for gene activation is somewhat surprising becauseOCA-B in M12 cells synergistically potentiates activa-
phosphorylation of Ser-385 of the Oct-1 POU domaintion by Oct-2 at the 39 IgH enhancer, suggesting that
by PKA, which corresponds to S303 of Oct-2, preventsthese two proteins coactivate this enhancer element.
binding of Oct-1 to DNA derived from the histone H3This coregulation is also inactivated if the threonine and
promoter (Segil et al., 1991). In contrast, phosphorylationserine residues in the linker region of Oct-2 are mutated
of Oct-2 at this site by PKA has no effect on DNA bindingto alanine. These results suggest that Oct-2 and OCA-B
in vitro. Phosphorylation of Oct-2 correlates with its acti-are critical for full activation of B cells and that their
vation and most certainly binding to the 39 IgH enhancer.functions can be studied through their interactions with
The binding of phosphorylated Oct-2 to the enhancerthe 39 IgH enhancer.
could be a signal for subsequent association of tran-
M12 cells are Ig nonsecreting (Laskov et al., 1981),
scription coactivators similar to the interaction of CREB
Syndican-1 bearing (unpublished data) early plasma cells. and CBP. This dependence might explain the decreased
This would be consistent with considering M12 cells as activities of variants of Oct-2, which are defective for
arrested at a very early stage in the development of phosphorylation in vivo.
terminal plasma cells, a transition that is crucially depen- Although the S/T-rich C terminus of Oct-2 has been
dent upon Oct-2 (Humbert and Corcoran, 1997). LPS- shown to be a target for phosphorylation in Hela cells
inducible expression of Blimp-1 reported here also sup- (Tanaka and Herr, 1990), the functional importance of
ports this notion. Therefore, it should not be surprising this modification has not been described. In contrast,
that the M12 cell line, as compared to other tumor B phosphorylation at T302 and S303, with the side chain
cell lines, is unusually dependent for expression of the of S303 being most critical, is probably indispensable for
IgH promoter upon the interaction between Oct-2 and activation of the 39 IgH enhancer during B cell activation.
the 39 IgH enhancer and is responsive to expression of There are several precedents for PKC phosphorylation
the Oct-2 and OCA-B proteins. of specific transcriptional factors during B cell develop-
Oct-22/2 mice exhibit abrogated B cell maturation, ment. For example, CREB has been shown to be phos-
reduced secretion levels of certain Ig isotypes, and defi- phorylated by PKC in response to cross-linking of sur-
ciency in response to TI and TD antigens (Corcoran et face Ig on B cells (Xie and Rothstein, 1995). The
al., 1993; Humbert and Corcoran, 1997). It is likely that importance of PKC for normal B cell development is
part of this phenotype of deficiency in IgH expression illustrated by targeted disruption of the PKCb gene in
mice that exhibit phenotypes similar to X-linked immu-and perhaps class switching is due to Oct-2's interaction
nodeficiency (xid; Leitges et al., 1996). Our results sug-with the 39 IgH enhancer. The 39 enhancer is uniquely
gest another role for PKC in B cell activation: stimulationactive in late stage of B cells (Madisen and Groudine,
of phosphorylation of the B cell±differentiation factor1994; Chauveau et al., 1998; Ong et al., 1998) and large
Oct-2.deletions encompassing the whole sequence are defec-
OCA-B is required for the convergence of multipletive for transcription of IgH genes. The activation of the
signals during B cell activation (Qin et al., 1998). Mice39 IgH enhancer by Oct-2 is also specific when com-
that are OCA-B2/2 produce plasma cells but have re-pared to the lack of activity by Oct-1. Most previous
duced levels of circulating immunoglobulins and no ger-transcription assays both in vivo (Pfisterer et al., 1994;
minal centers. The low levels of serum IgG would beShah et al., 1997) and in vitro (Scheidereit et al., 1987;
consistent with a requirement for OCA-B in the full po-Pierani et al., 1990; Luo et al., 1992; Annweiler et al.,
tentiation of the 39 IgH enhancer. Stimulation of tran-1993) are not specific for overexpression of Oct-2 versus
scription by OCA-B from the enhancer is dependent
Oct-1. A few studies have shown that some artificial
upon phosphorylation of Oct-2. Because OCA-B only
reporter constructs could be activated more effectively associates with DNA with high affinity when it binds in
by Oct-2 than by Oct-1, but these results were neither conjunction with either Oct-1 or Oct-2, its synergistic
cell type± or cell stage±specific (Tanaka and Herr, 1990; activity in M12 cells indicates the formation of a multi-
Annweiler et al., 1994; Pfisterer et al., 1994) and the protein complex on this enhancer and/or potentially the
preference for Oct-2 versus Oct-1 appeared to reflect promoter during B cell activation. These observations
differences in the activation domains of the proteins. are also consistent with these two proteins having over-
Oct-2-dependent 39 IgH enhancer activity is dramati- lapping dependencies in B cell activation, with the Oct-
cally stimulated by LPS in M12 cells. This is consistent 22/2 phenotype being more severe than the OCA-B2/2
with the proposal that Oct-2 is a component of the sig- phenotype.
naling pathway used by LPS for normal activation of B The structure of a ternary complex of the POU domain
cells (Corcoran and Karvelas, 1994; Humbert and Corco- of Oct-1, a DNA segment containing the octamer motif
ran, 1997). The specific PKC inhibitor staurosporine re- and 44 residues of OCA-B protein, has been recently
determined at the atomic level (Chasman et al., 1999).duces the bulk level of phosphorylation of Oct-2 protein
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by the denaturing method exactly as described previously (Tang etAll the residues in the POU domain of Oct-1 contacting
al., 1996). Renatured proteins (200 ng) were phosphorylated in vitroOCA-B are conserved in Oct-2, suggesting that Oct-2
by 8 U or 80 U of PKA in 10 ml with 5 mCi g-32P-ATP (6000 Ci/mmol,POU/OCA-B/DNA complex should also adopt identical
NEN) and 200 mM ATP at 308C for 5 min. Phosphorylated proteins
spatial arrangement. If this were the case, all of the side- (50±60 ng) were then added to the binding reaction and electropho-
chain contacts between Oct-2 and OCA-B would be on resis was done as described (Pomerantz and Sharp, 1994) except
that additional 100 ng of herring sperm DNA (GIBCO) was addedthe opposite side of the DNA duplex from the T302 and
per reaction.S303 residues of Oct-2. Hence, the binding of OCA-B
EMSA using Oct-1 or Oct-2 overexpressing nuclear extracts wasin this complex would not be expected to be dependent
performed as described (Schreiber et al., 1989) but buffer C wasupon phosphorylation of these residues. Supporting evi-
supplemented with phosphatase/protease inhibitors (5 mM NaF, 5
dence is obtained from formation of Oct-2/OCA-B/DNA mM b-phosphoglycerol, 10 mM Na3P2O7, 1 mM Okadaic acid, 1 mM
complexes with the alanine mutants of Oct-2. However, EDTA, 1 mM EGTA, 1 mg/ml aprotinin, and 1 mg/ml leupeptin). For
supershift experiments with OCA-B, nuclear extracts were incu-synergistic activation of the enhancer by OCA-B and
bated with DNA for 20 min at 228C; 150 ng recombinant GST-OCA-BOct-2 is inactivated by mutations of these residues to
fusion protein (Cepek et al., 1996) was then added and incubatedalanine. These observations would be explained if, as
for additional 20±30 min at 228C before electrophoresis.proposed above, phosphorylation of Oct-2 signals the
binding of a coactivator, which synergistically acts with
Two-Dimensional Phosphopeptide MappingOCA-B to stimulate transcription.
His-Oct-2 POU proteins (z60 ng) were reacted with 0.04 U PKC
according to manufacturer's manual (Promega) in the presence of
Experimental Procedures 5 mCi g-32P-ATP (6000 Ci/mmol, NEN) and 200 mM ATP at 308C for
5±10 min. Phosphoproteins were then resolved in a 4%±20% SDS-
Plasmid Construction PAGE and the two-dimensional phosphopeptide mapping was per-
FLAG tag was inserted in-frame N-terminal to Oct-1, Oct-2, or their formed essentially as described (van der Geer and Hunter, 1994),
mutant variants in pCG-Oct-1 or pCG-Oct-2 (Tanaka and Herr, 1990) except that plastic cellulose TLC plates (EM Science) and a
by add-on PCR. POU domains of Oct-1 and Oct-2 and its alanine Multiphor II electrophoretic system were used (Pharmacia).
mutants were subcloned in-frame downstream of hexa-His tag in Synthesized peptide (1.5 mg) corresponding to amino acids 299±
pQE30 (Qiagen). The murine 39 IgH enhancer fragments (HS1/2, 4.3 310 (POU2 WT, KKRTSIETNVR; AnaSpec) was phosphorylated by
kb; HS3, 1.2 kb; HS4, 1.4 kb) was isolated by digesting pHS1234 0.04 U of PKC as above. The resulting phosphopeptide was purified
(Madisen and Groudine, 1994) with BssHII and blunt-ended ligated by Sep-Pak C18 Light (Waters) and 5% was subject to trypsin diges-
to the SalI site of ªpGL-3 Basicº luciferase reporter vector (Promega). tion and two-dimensional phosphopeptide mapping analogously.
The orientation of the enhancer insert was verified by restriction
digestions as identical to their genomic organization relative to the
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